Gloria Lin

Gloria Lin

Company: Trillium Therapeutics Inc

Job title: Director, Translational Research


TTI-622 and TTI-621 Target the CD47 “Don’t Eat Me” Signal on Tumor Cells 4:30 pm

TTI-622 and TTI-621 are soluble SIRPαFc decoy receptors that neutralize the suppressive effects of CD47 and deliver an activating signal to macrophages through Fc receptors. TTI-622 and TTI-621 are differentiated from other CD47 blocking agents by the lack of RBC binding and greater monotherapy activity. Emerging clinical data for both agents will be discussedRead more

day: Clinical Development - Day 1 pm2

Panel Discussion: Exploring How Best to Harness the Anti-Tumor Potential of Macrophages 3:00 pm

Discussing the resistance mechanisms against myeloid cell recruitment inhibition and lack of effect on tissueresident TAM populations Considering the risk of accelerated metastasis following withdrawal of CCL2/CCR2 inhibitors Do we need to look to alternative targets to overcome these limitations?Read more

day: Clinical Development - Day 1 pm

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.